Fortrea Holdings Inc. FTRE 深 沪
等待开盘 04-01 09:30:00 美东时间
9.42
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 9.42
- 总市值 8.81亿
- 52周最高 18.67
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.97
- 委 比 0.00%
- 总股本 9350.00万
- 历史最高 41.02
- 量 比 0
- 振 幅 0.00%
- 历史最低 3.97
- 每 手 1
- 风险率 3.98%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
TD Cowen Upgrades Fortrea Holdings to Buy, Announces $15 Price Target
TD Cowen analyst Charles Rhyee upgrades Fortrea Holdings (NASDAQ:FTRE) from Hold to Buy and announces $15 price target.
03-10 02:23
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
Baird Maintains Outperform on Fortrea Holdings, Lowers Price Target to $16
Baird analyst Eric Coldwell maintains Fortrea Holdings (NASDAQ:FTRE) with a Outperform and lowers the price target from $19 to $16.
02-27 20:49
Fortrea Appoints Oren Cohen as CMO and Scott Dove as President of Clinical Pharmacology Services
Fortrea Appoints Oren Cohen as CMO and Scott Dove as President of Clinical Pharmacology Services Fortrea Holdings Inc. has expanded its executive team, appointing Oren Cohen, MD, as Chief Medical Officer and Scott Dove, PhD, as President of Clinical Pharmacology Services. Dr. Cohen will now focus so
02-17 20:00
美股大行评级 | 潜在涨幅258.31%！Tempest Therapeutics获HC Wainwright上调评级至"买入"，目标价11美元
今日重点评级关注：HC Wainwright & Co.：上调Tempest Therapeutics评级至"买入"，目标价11美元；Guggenheim：维持Sportradar Gr"买入"评级，目标价从34美元升至35美元
01-23 19:46
TD Cowen Maintains Hold on Fortrea Holdings, Raises Price Target to $15
TD Cowen analyst Charles Rhyee maintains Fortrea Holdings (NASDAQ:FTRE) with a Hold and raises the price target from $7 to $15.
01-23 00:47
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
Truist Securities Upgrades Fortrea Holdings to Buy, Raises Price Target to $22
Truist Securities analyst Jailendra Singh upgrades Fortrea Holdings (NASDAQ:FTRE) from Hold to Buy and raises the price target from $12 to $22.
01-08 20:38
Fortrea upgraded at Evercore ISI on management changes
Fortrea Holdings (FTRE) traded higher on Tuesday after Evercore ISI upgraded the contract research organization, citing positives in its recent leadership transition, in which a veteran life sciences ...
01-07 02:14
